ethyl 2-(6-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazin-3-yl)acetate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: ethyl 2-(6-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazin-3-yl)acetate
• 英文别名: ethyl (+/-)-6-chloro-3,4-dihydro-2H-1,4-benzoxazine-3-acetate；ethyl 2-(6-chloro-3,4-dihydro-2H-1,4-benzoxazin-3-yl)acetate
• 化学式: C₁₂H₁₄ClNO₃
• 分子量: 255.701
• InChiKey: BOUMWQQBKCTPAS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 2-(6-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazin-3-yl)acetate 在 1-丙基磷酸酐 、 三乙胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 水 、 乙酸乙酯 为溶剂， 反应 5.0h， 生成 2-(6-chloro-4-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carbonyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-3-yl)-N-methylacetamide
  参考文献：
  名称：

  Identification of Mineralocorticoid Receptor Modulators with Low Impact on Electrolyte Homeostasis but Maintained Organ Protection

  摘要：

  The mechanism-based risk for hyperkalemia has limited the use of mineralocorticoid receptor antagonists (MRAs) like eplerenone in cardio-renal diseases. Here, we describe the structure and property-driven lead generation and optimization, which resulted in identification of MR modulators (S)-1 and (S)-33. Both compounds were partial MRAs but still demonstrated equally efficacious organ protection as eplerenone after 4 weeks of treatment in uni-nephrectomized rats on high-salt diet and aldosterone infusion. Importantly, and in sharp contrast to eplerenone, this was achieved without substantial changes to the urine Na+/K+ ratio after acute treatment in rat, which predicts a reduced risk for hyperkalemia. This work led to selection of (S)-1 (AZD9977) as the clinical candidate for treating MR-mediated cardio-renal diseases, including chronic kidney disease and heart failure. On the basis of our findings, we propose an empirical model for prediction of compounds with low risk of affecting the urinary Na+/K+ ratio in vivo.

  DOI：

  10.1021/acs.jmedchem.8b01523
• 作为产物：
  描述：

  6-氯-2H-1,4-苯并噁嗪-3(4H)-酮 在 4-二甲氨基吡啶 、 三乙基硼氢化锂 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 1.5h， 生成 ethyl 2-(6-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazin-3-yl)acetate
  参考文献：
  名称：

  Identification of Mineralocorticoid Receptor Modulators with Low Impact on Electrolyte Homeostasis but Maintained Organ Protection

  摘要：

  The mechanism-based risk for hyperkalemia has limited the use of mineralocorticoid receptor antagonists (MRAs) like eplerenone in cardio-renal diseases. Here, we describe the structure and property-driven lead generation and optimization, which resulted in identification of MR modulators (S)-1 and (S)-33. Both compounds were partial MRAs but still demonstrated equally efficacious organ protection as eplerenone after 4 weeks of treatment in uni-nephrectomized rats on high-salt diet and aldosterone infusion. Importantly, and in sharp contrast to eplerenone, this was achieved without substantial changes to the urine Na+/K+ ratio after acute treatment in rat, which predicts a reduced risk for hyperkalemia. This work led to selection of (S)-1 (AZD9977) as the clinical candidate for treating MR-mediated cardio-renal diseases, including chronic kidney disease and heart failure. On the basis of our findings, we propose an empirical model for prediction of compounds with low risk of affecting the urinary Na+/K+ ratio in vivo.

  DOI：

  10.1021/acs.jmedchem.8b01523

文献信息

• 3-(2-aminomethyl)-4-[3-trifluoromethyl)benzoyl]-3-4
  申请人：Synthelabo

  公开号：US05550125A1

  公开（公告）日：1996-08-27

  Compounds of the general formula (I) ##STR1## wherein R.sub.1 represents a hydrogen, fluorine or chlorine atom or a methyl, C.sub.1 -C.sub.3 alkoxy or nitro group; R.sub.3 represents a hydrogen atom or a C.sub.1 -C.sub.3 alkyl group; R.sub.4 represents a 2,3-dihydro-1H-inden-2-yl, 2,3-dihydro-1H-inden-1-yl or 1,2,3,4-tetrahydronaphthalen-1-yl group; or alternatively R.sub.3 and R.sub.4 complete, with the nitrogen atom to which they are attached, a 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indol-2-yl, 1,2,3,4-tetrahydro-9H-pyrido[4,3-b]indol-3-yl, 4,5,6,7-tetrahydrothieno[2,3-c]pyrid-6-yl, 4,5,6,7-tetrahydrothieno[3,2-c]pyrid-6-yl or 2,3-dihydro-1H-isoindol-2-yl group; are useful for the treatment and prevention of cerebral disorders.

  通式(I)的化合物##STR1##，其中R.sub.1代表氢、氟或氯原子或甲基、C.sub.1 -C.sub.3烷氧基或硝基；R.sub.3代表氢原子或C.sub.1 -C.sub.3烷基；R.sub.4代表2,3-二氢-1H-茚-2-基、2,3-二氢-1H-茚-1-基或1,2,3,4-四氢萘-1-基；或者R.sub.3和R.sub.4与它们连接的氮原子共同构成1,2,3,4-四氢-9H-吡啶并[3,4-b]吲哚-2-基、1,2,3,4-四氢-9H-吡啶并[4,3-b]吲哚-3-基、4,5,6,7-四氢噻吩并[2,3-c]吡啶-6-基、4,5,6,7-四氢噻吩并[3,2-c]吡啶-6-基或2,3-二氢-1H-异吲哚-2-基；对于治疗和预防脑部疾病很有用。
• Identification of Mineralocorticoid Receptor Modulators with Low Impact on Electrolyte Homeostasis but Maintained Organ Protection
  作者：Kenneth L. Granberg、Zhong-Qing Yuan、Bo Lindmark、Karl Edman、Johan Kajanus、Anders Hogner、Marcus Malmgren、Gavin O’Mahony、Anneli Nordqvist、Jan Lindberg、Stefan Tångefjord、Michael Kossenjans、Christian Löfberg、Jonas Brånalt、Dongmei Liu、Nidhal Selmi、Grigorios Nikitidis、Peter Nordberg、Ahlke Hayen、Anna Aagaard、Eva Hansson、Majlis Hermansson、Ida Ivarsson、Rasmus Jansson-Löfmark、Ulla Karlsson、Ulrika Johansson、Lena William-Olsson、Judith Hartleib-Geschwindner、Krister Bamberg

  DOI：10.1021/acs.jmedchem.8b01523

  日期：2019.2.14

  The mechanism-based risk for hyperkalemia has limited the use of mineralocorticoid receptor antagonists (MRAs) like eplerenone in cardio-renal diseases. Here, we describe the structure and property-driven lead generation and optimization, which resulted in identification of MR modulators (S)-1 and (S)-33. Both compounds were partial MRAs but still demonstrated equally efficacious organ protection as eplerenone after 4 weeks of treatment in uni-nephrectomized rats on high-salt diet and aldosterone infusion. Importantly, and in sharp contrast to eplerenone, this was achieved without substantial changes to the urine Na+/K+ ratio after acute treatment in rat, which predicts a reduced risk for hyperkalemia. This work led to selection of (S)-1 (AZD9977) as the clinical candidate for treating MR-mediated cardio-renal diseases, including chronic kidney disease and heart failure. On the basis of our findings, we propose an empirical model for prediction of compounds with low risk of affecting the urinary Na+/K+ ratio in vivo.